Stock listing

NASDAQ:RAPP Rapport Therapeutics, Inc. Stock

Home listing (NASDAQ) of Rapport Therapeutics, Inc.

Follow Rapport Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RAPP

$23.16 USD -0.24 (-1.0%)

Close on Nov 20, 2026

Past year -13.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$23.00 – $23.83 USDNov 20, 2026
Volume
437,720 sharesNov 20, 2026
Market cap
$1.37B USDAt the close on Nov 20, 2026 · price × 59.28M shares outstanding
52-week range
$22.06 – $52.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$23.30M USDMedian day 437,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rapport Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RAPP · Home$23.16 USD-0.24 (-1.0%)437,720$23.23$23.83$23.00$23.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RAPP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$23.16-0.24-1.0%$23.23$23.83$23.00437,720
$23.40-0.36-1.5%$23.70$25.00$22.91731,089
$23.76-1.06-4.3%$24.66$24.88$23.41522,764
$24.82-1.33-5.1%$25.78$26.14$24.63462,563
$26.15+0.30+1.2%$25.85$26.29$25.11315,633
$25.85-1.17-4.3%$26.76$26.90$25.45568,187
$27.02+1.06+4.1%$26.06$27.10$25.77626,291
$25.96-0.11-0.4%$25.83$26.90$25.30660,143
$26.07+1.63+6.7%$24.50$26.35$24.06789,005
$24.44+0.72+3.0%$23.72$24.52$22.95866,405
$23.72-2.21-8.5%$25.64$25.67$23.67706,810
$25.93+0.49+1.9%$26.12$26.36$25.27956,000
$25.44+0.31+1.2%$25.39$26.06$25.13822,403
$25.13+0.08+0.3%$25.16$26.16$24.221,327,415
$25.05+0.84+3.5%$23.94$25.43$23.86922,247
$24.21+1.71+7.6%$22.58$25.76$22.583,094,708
$22.50-5.04-18.3%$22.59$23.94$22.065,940,919
$27.54+2.21+8.7%$25.11$28.31$25.11601,911
$25.33-0.60-2.3%$26.02$27.95$25.101,040,733
$25.93-0.60-2.3%$27.54$27.76$25.711,185,000
$26.53+1.47+5.9%$26.17$27.89$25.811,458,200
$25.06-4.31-14.7%$29.91$29.91$24.692,158,300
$29.37+0.77+2.7%$30.33$31.31$26.738,200,200
$28.60+1.03+3.7%$27.57$29.10$27.57299,900
$27.57-2.00-6.8%$29.50$29.75$26.93412,100
$29.57+1.24+4.4%$29.12$30.48$28.68334,900
$28.33-0.66-2.3%$28.71$29.31$28.10304,000
$28.99-1.16-3.8%$30.00$30.01$28.68310,000
$30.15-0.50-1.6%$30.65$30.99$30.00127,100
$30.65+0.80+2.7%$29.73$31.20$29.50247,900
$29.85-1.01-3.3%$30.62$30.62$29.45236,800
$30.86-0.29-0.9%$30.81$31.35$30.46315,000
$31.15-1.04-3.2%$32.92$34.00$30.01235,600
$32.19+0.02+0.1%$32.22$32.71$31.53198,500
$32.17-0.66-2.0%$33.33$34.48$31.77276,300
$32.83-0.77-2.3%$33.52$34.32$32.80326,800
$33.60+0.58+1.8%$33.17$34.05$32.62581,700
$33.02-0.42-1.3%$33.25$33.66$32.12626,100
$33.44-0.47-1.4%$33.48$34.00$32.36552,300
$33.91+0.08+0.2%$33.80$34.89$33.05711,800
$33.83-0.30-0.9%$34.15$34.21$31.58848,500
$34.13-7.34-17.7%$41.01$41.47$33.38743,700
$41.47+1.81+4.6%$39.97$41.55$37.94900,200
$39.66-0.79-2.0%$40.70$42.18$39.11617,000
$40.45-1.50-3.6%$41.89$43.00$40.29998,100
$41.95+0.56+1.4%$42.13$42.90$41.39397,300
$41.39-1.29-3.0%$42.82$43.67$41.23387,000
$42.68-1.32-3.0%$43.87$43.98$41.76189,300
$44.00+0.38+0.9%$44.30$44.90$43.36196,900
$43.62+0.16+0.4%$44.21$44.30$43.01251,800
$43.46-0.425-1.0%$43.35$44.00$42.65319,300
$43.89-2.205-4.8%$45.17$45.42$43.13437,700
$46.09+0.32+0.7%$45.01$47.00$44.67489,400
$45.77-1.88-3.9%$47.63$48.00$45.52279,900
$47.65-1.04-2.1%$48.85$49.14$47.08277,000
$48.69+0.13+0.3%$48.50$50.34$47.73294,700
$48.56-0.11-0.2%$48.17$49.38$47.90148,600
$48.67-0.10-0.2%$48.72$49.33$47.51221,000
$48.77-2.06-4.1%$50.15$50.68$48.37332,700
$50.83-1.67-3.2%$51.88$52.93$50.60382,800
$52.50+1.33+2.6%$50.95$52.83$50.01275,300
$51.17+1.84+3.7%$49.88$51.38$49.00324,500
$49.33+1.09+2.3%$48.16$50.34$47.44365,422
$48.24+0.39+0.8%$48.36$48.50$47.48140,900
$47.85-1.22-2.5%$48.58$48.78$47.00323,700
Ticker
NASDAQ:RAPP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Rapport Therapeutics, Inc. news

Rapport Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 44 in all · newest Nov 4, 2026 · oldest 2024
Decks
11 decks · latest Oct 20, 2026

Where Rapport Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RAPP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RAPPBOATSUnited StatesUSD

Valuation

EV/sales 49.4× against a median of 19.0×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$987.3M USD
P/E
Loss
EV/sales
49.4×
EV/EBITDA
Negative EBITDA
Price/book
3.5×
Gross margin
Not reported
Operating margin
−838.1%
Net margin
−752.4%
Debt to equity
0.0×
Beta vs S&P 500
1.16

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rapport Therapeutics, Inc. · NASDAQ:RAPPUS$1.37BUS$987.3Mn/a49.4×n/a3.5×−752.4%0.0×1.16
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Tyra Biosciences, Inc. · NASDAQ:TYRAUS$1.39BUS$694.9Mn/an/an/a2.0×n/a0.0×0.40
Wuhan Healthgen Biotechnology Corp Class A · SSE:688765US$1.37BUS$1.37Bn/a164×n/a3.3×−252.8%0.1×n/a
Immunocore Holdings plc · NASDAQ:IMCRUS$1.36BUS$463.6Mn/a1.1×n/a3.3×−7.5%0.0×0.62
Nanobiotix SA · EURONEXT:NANOUS$1.36BUS$1.36Bn/a41.7×n/an/a−80.8%n/an/a
uniQure N.V. · NASDAQ:QUREUS$1.36BUS$739.1Mn/a36.6×n/a4.6×n/a0.2×1.25
UroGen Pharma Ltd. · NASDAQ:URGNUS$1.36BUS$1.46Bn/a5.8×n/an/a−26.3%n/a1.23
Median of the othersUS$1.38BUS$871.1M4.8×19.0×2.4×−26.3%0.1×1.23

Forecasts

15 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
64.21 USD · Analysts' mean
EPS, year to Dec 2026
-3.25 · 12 analysts
Revenue, year to Dec 2026
20.01M · 15 analysts

Team and board

Officers

OfficerRole
Troy IgnelziChief Financial Officer
Abe CeesayPresident
Cheryl GaultChief Operating Officer
David BredtFounder, Chief Scientific Officer
Jeffrey SevignyChief Medical Officer
Kathy WilkinsonChief People Officer
Steve PaulFounder; Chairman, Board of Directors
Swamy YeleswaramChief Development Officer

Board

DirectorRole
Steve PaulFounder; Chairman, Board of Directors
John MaraganoreVenture Partner, ARCH Venture Partners and Atlas Ventures
Reid HuberPartner, Third Rock Ventures

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+1.9%
Q2 2026Aug 5, 2026 · Before open+0.6%
Q1 2026May 7, 2026 · Before open+7.7%
Q4 2025Mar 17, 2026−4.1%
Q3 2025Nov 6, 2025 · Before open−3.1%
Q2 2025Aug 7, 2025 · Before open+5.5%
Q1 2025May 8, 2025 · Before open+4.2%
Q4 2024Mar 11, 2025+21.0%
Q3 2024Nov 7, 2024 · Before open+2.9%
Q2 2024Aug 8, 2024 · Before open−1.6%
All 11 quarters
QuarterResultsShare move
Q1 2024May 29, 2024

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update26 slidesOct 20, 2026
Investor Presentation (August 2026)Investor deck51 slidesAugust 2026
American Academy of Neurology Annual Meeting 2026Conference13 slidesApr 21, 2026
Investor Presentation (April 2026)Investor deck50 slidesApr 21, 2026
Investor Presentation (January 2026)Investor deck47 slidesJan 7, 2026
Technical Presentation (September 2025)Technical22 slidesSep 8, 2025
Investor Presentation (August 2025)Investor deck32 slidesAug 7, 2025
Investor Day (June 2025)Investor day46 slidesJun 2, 2025
Investor Presentation (March 2025)Investor deck38 slidesMar 3, 2025
Epilepsy Foundation Pipeline Conference 2024Conference8 slidesSep 25, 2024
All 11 decks
DeckKindSlidesDate
Investor Presentation (May 2024)Investor deck40 slidesMay 2024

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Closed: US$10M raised · US$25.05 a share
Nov 4, 2026
Public offering of common stock and pre-funded warrants
Closed: US$175M raised · US$21 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), BTIG (co-lead), Citizens Capital Markets (co-lead)
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
2.25% convertible senior notes due 2032
Closed: US$172.5M raised · Morgan Stanley +2
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead)
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
Private placement of common stock
Closed: US$30M raised · US$21 a share · Morgan Stanley +2
Dealers: Morgan Stanley, Leerink Partners, Evercore ISI
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
Public offering of common stock
Update: about US$250M · US$26 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead)
Sep 9, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Jun 6, 2024.

Price
US$17.00 a share
Shares offered
8,000,000 shares of common stock
Offering size
US$136 million
Underwriters' option
Up to 1,200,000 more shares
Underwriters
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel · In the order on the cover
Shares delivered
On or about Jun 10, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceMar 27, 2024
Filed publiclyMay 17, 2024
Amended onceJun 3, 2024
Shares registered with an exchangeJun 4, 2024
Declared effective by the SECJun 6, 2024
Final prospectus, with the priceJun 7, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jun 7, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue000
Cost of revenue1.02M839.0K112.0K15.0K
Gross profit-1.02M-839.0K-112.0K-15.0K
Research and development94.8M60.9M28.0M9.12M
Selling, general and administrative30.3M22.1M8.18M1.37M
Operating income-125.1M-83.1M-36.2M-10.4M
Depreciation and amortization1.02M839.0K112.0K15.0K
EBITDA-124.1M-82.2M-36.1M-10.4M
Interest expense0285.0K
Income before tax-111.5M-78.3M-34.8M-10.7M
Income tax0010.0K
Net income-111.5M-78.3M-34.8M-10.7M
Earnings per share, basic-2.86-3.78-23.10-0.53
Earnings per share, diluted-2.86-3.78-23.10

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents52.6M56.8M70.2M31.2M
Short-term investments437.9M248.5M77.3M0
Receivables0
Current assets498.6M309.8M150.9M31.3M
Property, plant and equipment2.98M3.53M1.92M
Total assets512.4M314.9M155.4M31.6M
Accounts payable4.19M1.95M2.50M1.45M
Current liabilities19.0M8.77M8.80M1.66M
Total debt11.5M1.48M2.15M10.4M
Total liabilities27.8M9.51M14.5M12.1M
Shareholders' equity484.7M305.4M-25.6M19.5M
Shares outstanding47.8M36.6M4.17M20.1M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-87.5M-64.8M-27.2M-3.24M
Capital spending-616.0K-2.40M-1.64M-284.0K
Free cash flow-88.1M-67.2M-28.8M-3.53M
Cash from investing-187.5M-170.1M-78.9M-5.28M
Cash from financing270.8M221.6M145.1M39.7M
Share buybacks-1.00K0-4.00K
Change in cash-4.16M-13.3M39.1M31.2M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
8-K · Current reportOct 30, 2026ResultsSEC
424B5 · ProspectusOct 30, 2026Offer documentSEC
424B5 · ProspectusOct 30, 2026Offer documentSEC
305B2Oct 29, 2026Other filingsSEC
FWP · Free writing prospectusOct 28, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
FWP · Free writing prospectusOct 28, 2026Offer documentSEC
FWP · Free writing prospectusOct 27, 2026Offer documentSEC
FWP · Free writing prospectusOct 27, 2026Offer documentSEC
424B5 · ProspectusOct 27, 2026Offer documentSEC
424B5 · ProspectusOct 27, 2026Offer documentSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
8-K · Current reportOct 20, 2026Current reportSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
144 · Notice of proposed saleAug 24, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 15, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
144 · Notice of proposed saleMay 27, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
144 · Notice of proposed saleMay 7, 2026Other filingsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
8-K · Current reportApr 21, 2026Current reportSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
144 · Notice of proposed saleApr 10, 2026Other filingsSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
144 · Notice of proposed saleMar 30, 2026Other filingsSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
144 · Notice of proposed saleMar 25, 2026Other filingsSEC
S-3ASR · Registration statementMar 10, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 10, 2026Offer documentSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
8-K · Current reportJan 7, 2026Current reportSEC
424B5 · ProspectusJan 7, 2026Offer documentSEC
8-K · Current reportJan 7, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 22, 2025Big-stake noticeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 18, 2025Big-stake noticeSEC
144 · Notice of proposed saleSep 17, 2025Other filingsSEC
144 · Notice of proposed saleSep 17, 2025Other filingsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
8-K · Current reportSep 10, 2025Material contractSEC
424B5 · ProspectusSep 10, 2025Offer documentSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
424B5 · ProspectusSep 8, 2025Offer documentSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
8-K · Current reportSep 8, 2025Current reportSEC
8-K · Current reportSep 8, 2025Current reportSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 10, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 10, 2025Other filingsSEC
CORRESP · Letter to the SECJul 7, 2025Other filingsSEC
CORRESP · Letter to the SECJul 7, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 7, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 7, 2025Other filingsSEC
S-3 · Registration statementJul 1, 2025Offer documentSEC
S-3 · Registration statementJul 1, 2025Offer documentSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
144 · Notice of proposed saleJun 16, 2025Other filingsSEC
8-K · Current reportJun 2, 2025Current reportSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 3, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 7, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 7, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 7, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 7, 2024Insider tradeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC

This page holds 200 of 254 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rapport Therapeutics, Inc.’s releases · as of Nov 4, 2026

Common shares
59,279,630
Fully diluted
59,279,630

Fully diluted

LineSharesAs of
Common shares59,279,630Nov 2, 2026

Share count over time

CountShares
Nov 22, 202659,279,630
Nov 2, 202660,708,201
Nov 2, 202659,279,630

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity7.2M12.1%US$242MSep 30, 2026
Trv Gp V, LLC6.28M10.6%US$211MSep 30, 2026
ARCH Venture Management, LLC3.73M6.3%US$125MSep 30, 2026
Capital Group3.21M5.4%US$108MSep 30, 2026
Goldman Sachs2.97M5.0%US$99.9MSep 30, 2026
BlackRock2.88M4.9%US$96.8MSep 30, 2026
Cormorant Asset Management, LP2.46M4.1%US$82.6MSep 30, 2026
Vanguard2.24M3.8%US$75.2MSep 30, 2026
Sofinnova Investments, Inc.1.9M3.2%US$64MSep 30, 2026
Johnson & Johnson1.78M3.0%US$60MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Polar Capital Holdings Plc1.6M2.7%US$53.9MSep 30, 2026
Baker Bros. Advisors LP1.55M2.6%US$52MSep 30, 2026
Trv Gp VI, LLC969K1.6%US$32.6MSep 30, 2026
State Street916K1.5%US$30.8MSep 30, 2026
Geode Capital870K1.5%US$29.2MSep 30, 2026
Perceptive Advisors LLC724K1.2%US$24.3MSep 30, 2026
T. Rowe Price642K1.1%US$21.6MSep 30, 2026
Siren, L.L.C.641K1.1%US$21.6MSep 30, 2026
AllianceBernstein630K1.1%US$21.2MSep 30, 2026
Artisan Partners Limited Partnership438K0.74%US$14.7MSep 30, 2026
Dimensional403K0.68%US$13.5MSep 30, 2026
Candriam S.C.A.347K0.58%US$11.7MSep 30, 2026
Algert Global LLC304K0.51%US$10.2MSep 30, 2026
Schwab304K0.51%US$10.2MSep 30, 2026
Northern Trust295K0.50%US$9.92MSep 30, 2026
Sio Capital Management, LLC291K0.49%US$9.79MSep 30, 2026
UBS290K0.49%US$9.73MSep 30, 2026
Nuveen267K0.45%US$8.97MSep 30, 2026
Kennedy Capital Management LLC252K0.42%US$8.46MSep 30, 2026
Casdin Capital, LLC200K0.34%US$6.72MSep 30, 2026
Invesco182K0.31%US$6.12MSep 30, 2026
Lord, Abbett & Co. LLC179K0.30%US$6.02MSep 30, 2026
Artia Global Partners LP167K0.28%US$5.59MSep 30, 2026
Ghisallo Capital Management LLC150K0.25%US$5.04MSep 30, 2026
DAFNA Capital Management LLC142K0.24%US$4.77MSep 30, 2026
Ensign Peak Advisors, Inc127K0.21%US$4.26MSep 30, 2026
Swedbank AB117K0.20%US$3.94MSep 30, 2026
D. E. Shaw & Co., Inc.114K0.19%US$3.84MSep 30, 2026
Wellington109K0.18%US$3.67MSep 30, 2026
XTX Topco Ltd103K0.17%US$3.46MSep 30, 2026
Sphera Funds Management LTD.100K0.17%US$3.36MSep 30, 2026
Woodline Partners LP98,1280.17%US$3.3MSep 30, 2026
Neuberger Berman Group LLC95,8050.16%US$3.22MSep 30, 2026
Morgan Stanley86,9330.15%US$2.92MSep 30, 2026
Qube Research & Technologies Ltd86,2960.15%US$2.9MSep 30, 2026
BNY83,5650.14%US$2.81MSep 30, 2026
Susquehanna77,4430.13%US$2.6MSep 30, 2026
TD75,0780.13%US$2.48MSep 30, 2026
Bank of America70,1570.12%US$2.36MSep 30, 2026
Millennium68,1180.11%US$2.29MSep 30, 2026

This page holds 50 of 160 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
SMALLCAP World Fund Inc3.39M5.7%US$141MJun 30, 2026
Fidelity Growth Company Fund2.25M3.8%US$89MMay 31, 2026
Vanguard Total Stock Market Index Fund987K1.7%US$41.1MJun 30, 2026
iShares Russell 2000 ETF798K1.3%US$33.3MJun 30, 2026
Fidelity Growth Company K6 Fund687K1.2%US$27.1MMay 31, 2026
Fidelity Series Growth Company Fund592K1.00%US$23.4MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.572K0.96%US$23.8MJun 30, 2026
Select Biotechnology Portfolio428K0.72%US$16.9MMay 31, 2026
Fidelity Small Cap Index Fund335K0.57%US$13.7MJul 31, 2026
Vanguard Extended Market Index Fund329K0.55%US$13.7MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
AB Small Cap Growth Portfolio301K0.51%US$12.6MJun 30, 2026
iShares Russell 2000 Growth ETF264K0.45%US$11MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.230K0.39%US$9.57MJun 30, 2026
iShares Biotechnology ETF201K0.34%US$8.36MJun 30, 2026
Nuveen Quant Small Cap Equity Fund158K0.27%US$6.47MJul 31, 2026
Vanguard Russell 2000 Index Fund151K0.25%US$5.96MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF148K0.25%US$6.16MJun 30, 2026
Fidelity Extended Market Index Fund148K0.25%US$5.84MMay 31, 2026
Schwab U.S. Small-Cap ETF138K0.23%US$5.47MMay 31, 2026
Dimensional U.S. Small Cap ETF110K0.19%US$4.51MJul 31, 2026
Invesco Health Care Fund110K0.19%US$4.51MJul 31, 2026
iShares Micro-Cap ETF103K0.17%US$4.27MJun 30, 2026
SMALLCAP World Fund94,2280.16%US$3.93MJun 30, 2026
U.S. Small Cap Portfolio91,6370.15%US$3.76MJul 31, 2026
SmallCap Growth Fund I88,9940.15%US$3.65MJul 31, 2026
Vanguard Health Care Index Fund86,0240.15%US$3.4MMay 31, 2026
U.S. Micro Cap Portfolio79,6590.13%US$3.26MJul 31, 2026
iShares U.S. Pharmaceuticals ETF74,5200.13%US$3.11MJun 30, 2026
Schwab Small-Cap Index Fund74,3950.13%US$3.05MJul 31, 2026
Small Cap Core Portfolio69,5300.12%US$2.9MJun 30, 2026
Vanguard U.S. Momentum Factor ETF65,8990.11%US$2.6MMay 31, 2026
Master Small Cap Index Series57,2600.10%US$2.39MJun 30, 2026
Avantis U.S. Small Cap Equity ETF56,6400.10%US$2.24MMay 31, 2026
Fidelity Total Market Index Fund52,7250.09%US$2.08MMay 31, 2026
Allspring Common Stock Fund49,6330.08%US$2.07MJun 30, 2026
ALPS Medical Breakthroughs ETF49,2640.08%US$1.95MMay 31, 2026
Fidelity Series Total Market Index Fund43,4980.07%US$1.72MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF42,2550.07%US$1.76MJun 30, 2026
Lord Abbett Micro-Cap Growth Fund40,6500.07%US$1.67MJul 31, 2026
Nuveen Small Cap Blend Index Fund40,5400.07%US$1.66MJul 31, 2026
T. Rowe Price Health Sciences Portfolio38,0930.06%US$1.59MJun 30, 2026
EQ/2000 Managed Volatility Portfolio33,3340.06%US$1.39MJun 30, 2026
Nuveen Equity Index Fund33,2050.06%US$1.36MJul 31, 2026
Small Cap Equity Fund31,6500.05%US$1.32MJun 30, 2026
Fidelity Nasdaq Composite Index Fund28,9600.05%US$1.14MMay 31, 2026
Nuveen ESG Small-Cap ETF26,9130.05%US$1.1MJul 31, 2026
Fidelity Small Cap Growth Index Fund26,8210.05%US$1.12MJun 30, 2026
Vanguard Russell 2000 Value Index Fund23,0460.04%US$910KMay 31, 2026
LVIP State Street Small-Cap Index Fund21,8000.04%US$908KJun 30, 2026
Schwab U.S. Broad Market ETF20,3940.03%US$806KMay 31, 2026

This page holds 50 of 182 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Healy James
Director
Buy952,380USD 21.00US$20MOct 28, 2026
Healy James
Director
Buy6,395USD 21.00US$134KOct 28, 2026
Healy James
Director
Buy3,772USD 21.00US$79,212Oct 28, 2026
Healy James
Director
Buy6,933USD 21.00US$146KOct 28, 2026
Sanchez Ramiro
Director
Buy3,600USD 27.35US$98,478Oct 23, 2026
Maraganore John
Director
Buy8,239USD 26.38US$217KOct 22, 2026
Maraganore John
Director
Buy1,172USD 26.92US$31,547Oct 22, 2026
Paul Steven M
Director
Buy35,714USD 27.28US$974KOct 22, 2026
Young Wendy B.
Director
Buy3,789USD 26.39US$99,992Oct 22, 2026
Silva Paul M
Director
Buy3,680USD 27.07US$99,636Oct 22, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale2,210USD 29.16US$64,448Oct 21, 2026
Ignelzi Troy A.
Officer: Chief Financial Officer
Buy5,500USD 26.10US$144KOct 21, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale1,147USD 30.66US$35,167Oct 7, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale3,375USD 32.03US$108KOct 6, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale7,925USD 33.04US$262KSep 30, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale2,075USD 33.76US$70,043Sep 30, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale1,952USD 39.05US$76,226Sep 23, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale215USD 39.86US$8,570Sep 23, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale43USD 41.05US$1,765Sep 23, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale7,141USD 45.56US$325KSep 8, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale1,069USD 46.01US$49,185Sep 8, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale20,799USD 50.31US$1.05MAug 25, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale16,201USD 51.06US$827KAug 25, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale18,921USD 49.57US$938KAug 25, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale13,160USD 50.00US$658KAug 24, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale404USD 49.90US$20,160Aug 19, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale3,664USD 46.90US$172KAug 11, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale19,500USD 48.04US$937KAug 11, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale5,794USD 48.62US$282KAug 11, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale14,171USD 45.97US$651KAug 10, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale8,370USD 46.75US$391KAug 10, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale2,203USD 42.11US$92,768Jul 27, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale7USD 42.74US$299Jul 27, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale5,481USD 39.72US$218KJul 14, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale2,729USD 40.57US$111KJul 14, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale1,900USD 40.09US$76,171Jun 30, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale3,792USD 41.39US$157KJun 30, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale3,308USD 42.17US$139KJun 30, 2026
Gault Cheryl
Officer: Chief Operating Officer
Sale1,000USD 43.15US$43,150Jun 30, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale7,344USD 39.77US$292KJun 29, 2026
Ceesay Abraham
Director, Officer: Chief Executive Officer
Sale876USD 40.34US$35,338Jun 29, 2026
Third Rock Ventures V, L.P.
10% owner
Sale18,572USD 40.05US$744KMay 26, 2026
Third Rock Ventures V, L.P.
10% owner
Sale133,618USD 40.24US$5.38MMay 11, 2026
Third Rock Ventures VI, L.P.
10% owner
Sale5,018USD 40.31US$202KMay 8, 2026
Third Rock Ventures VI, L.P.
10% owner
Sale271,495USD 40.12US$10.9MMay 7, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale20,225USD 39.99US$809KApr 17, 2026
Third Rock Ventures VI, L.P.
10% owner
Sale426,005USD 40.32US$17.2MApr 17, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale10,200USD 35.08US$358KApr 14, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale9,165USD 34.97US$321KApr 13, 2026
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
Sale500USD 34.98US$17,490Apr 10, 2026

This page holds 50 of 51 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Third Rock Ventures V, L.P.13.10%6.28MJun 30, 2026Schedule 13G
Capital International Investors6.10%2.92MJun 30, 2026Schedule 13G
Cormorant Asset Management, LP5.12%2.46MSep 30, 2026Schedule 13G
BlackRock, Inc.5.03%2.4MDec 31, 2025Schedule 13G
Sofinnova Venture Partners XI, L.P. ("SVP XI")4.00%1.86MSep 11, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Healy
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past)
Director · Since at least Jun 6, 2024
Steve Paul
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 3, 2016 – Apr 1, 2022 · Past); Sigma-Aldrich Corp (Director · Nov 18, 2015 – Nov 18, 2015 · Past); Voyager Therapeutics, Inc. (Director · Nov 10, 2015 – Jun 3, 2021 · Past); Sage Therapeutics Inc (Director · Jul 1, 2015 – Jan 3, 2024 · Past)
Director · Since at least Jun 6, 2024
Troy Ignelzi
Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Contineum Therapeutics, Inc. (Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past)
Chief Financial Officer · Since at least Jun 6, 2024
Abraham Ceesay
Other companies: Charles River Laboratories International, Inc. (Director · Since at least May 20, 2025); Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); Cerevel Therapeutics Holdings Inc (President · Aug 5, 2022 – Feb 6, 2023 · Past)
Chief Executive Officer, Director · Since at least Jun 6, 2024
Jeffrey Tong
Other companies: Septerna, Inc. (Chairman of the Board · Since at least Oct 24, 2024); Maze Therapeutics, Inc. (Director · Jan 30, 2025 – Jan 30, 2025 · Past); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past)
Director · Jun 6, 2024 – Jun 6, 2024 · Past
John M. Maraganore
Other companies: Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Mar 3, 2026); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past)
Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Oct 22, 2026
Ramiro Sanchez
Other companies: Alto Neuroscience, Inc. (Director · Since at least Aug 12, 2025); Cerevel Therapeutics Holdings Inc (Chief Medical Officer · Oct 27, 2020 – Aug 1, 2024 · Past)
Director · Since at least Nov 7, 2024
Terry-Ann Burrell
Other companies: Recursion Pharmaceuticals, Inc. (Director · Apr 15, 2021 – Jul 1, 2024 · Past); Beam Therapeutics Inc. (Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past)
Director · Jun 6, 2024 – Jun 6, 2024 · Past
Cheryl Gault
Other companies: Cyclerion Therapeutics, Inc. (Chief Operating Officer · Jan 1, 2021 – Jan 20, 2022 · Past)
Chief Operating Officer · Since at least Jun 6, 2024
Paul M Silva
Other companies: Nurix Therapeutics, Inc. (Director · Since at least May 19, 2025)
Director · Since at least Jun 17, 2025
All 16 people
PersonSeat
Abe CeesayPresident · Since at least Jan 9, 2025
David BredtChief Scientific Officer · Since at least Jun 6, 2024
Jeffrey SevignyChief Medical Officer · Since at least Apr 1, 2025
Kathy WilkinsonChief People Officer · Since at least Nov 4, 2026
Reid HuberPartner, Third Rock Ventures · Since at least Nov 5, 2026
Swamy YeleswaramChief Development Officer · Since at least Nov 14, 2024

Open People

Log in to ask 6ix AI your own questions about Rapport Therapeutics, Inc.